awmsg logo



esomeprazole (Nexium®)


Reference No. 1185

Publication date:
01/05/2012


Last review date:
30/09/2016

Appraisal information

esomeprazole (Nexium®) 40 mg powder for solution for injection/infusion


Company: AstraZeneca UK Ltd
BNF category: Gastro-intestinal system
NMG meeting date: 21/02/2012
AWMSG meeting date: 21/03/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0712
Ministerial ratification: 25/04/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Esomeprazole (Nexium® IV) is recommended as an option for use within NHS Wales for gastric antisecretory treatment when the oral route is not possible, such as gastro-oesophageal reflux disease (GORD) in patients with erosive reflux oesophagitis and/or severe symptoms of reflux for children and adolescents aged 1–18 years of age. AWMSG is of the opinion that esomeprazole (Nexium® IV) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download